Send us Feedback

Medicines Company (MDCO)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
Medicines (MDCO) Showing Bearish Technicals With Resistance At $20.03
Market Intelligence Center  7 hrs ago  Comment 
Medicines (NASDAQ:MDCO) closed Friday's unsure trading session at $19.74. In the past year, the stock has hit a 52-week low of $12.33 and 52-week high of $22.82. Medicines (MDCO) stock has been showing support around $19.51 and resistance in the...
Potential Medicines (MDCO) Trade Targets 20.22% Return
Market Intelligence Center  Apr 17  Comment 
Medicines (NASDAQ:MDCO) closed Monday's reticent trading session at $20.05. In the past year, the stock has hit a 52-week low of $12.33 and 52-week high of $22.82. Medicines (MDCO) stock has been showing support around $19.52 and resistance in the...
Medicines (MDCO) Could Fall Through $19.12 Support Level
Market Intelligence Center  Apr 11  Comment 
Medicines (NASDAQ:MDCO) closed Tuesday's deflating trading session at $19.43. In the past year, the stock has hit a 52-week low of $12.33 and 52-week high of $22.82. Medicines (MDCO) stock has been showing support around $19.12 and resistance in...
The Medicines Company to Announce First Quarter 2012 Financial Results on Wednesday, April 25, 2012
Marketwire  Apr 10  Comment 
PARSIPPANY, NJ -- (Marketwire) -- 04/10/12 -- The Medicines Company (NASDAQ: MDCO) has scheduled its quarterly conference call for Wednesday, April 25th at 8:30 a.m. Eastern Time to discuss first quarter 2012 financial results, operational
Medicines (MDCO) Showing Bullish Technicals With Resistance At $21.05
Market Intelligence Center  Mar 20  Comment 
Medicines Company (NASDAQ: MDCO) closed Monday's trading session at $20.57. In the past year, the stock has hit a 52-week low of $12.33 and 52-week high of $22.82. Medicines (MDCO) stock has been showing support around $20.01 and resistance in the...
Medicines (MDCO) Showing Bullish Technicals But Could Fall Through $20.22 Support
Market Intelligence Center  Mar 8  Comment 
Medicines Company (NASDAQ: MDCO) closed Wednesday's trading session at $20.57. In the past year, the stock has hit a 52-week low of $12.33 and 52-week high of $22.82. Medicines (MDCO) stock has been showing support around $20.22 and resistance in...
Medicines (MDCO) Could Fall Through $21.42 Support Level
Market Intelligence Center  Feb 28  Comment 
Medicines Company (NASDAQ: MDCO) closed Monday's trading session at $21.95. In the past year, the stock has hit a 52-week low of $12.33 and 52-week high of $22.82. Medicines (MDCO) stock has been showing support around $21.42 and resistance in the...
UPDATE: Auriga Raises Price Target on the Medicines Company to $25
Benzinga  Feb 23  Comment 
According to Auriga, the Medicines Company (NASDAQ: MDCO) price target is raised to $25. Auriga said that MDCO had a strong quarter due to high demand of Angiomax, with results handily beating consensus on both revenue and EPS. “We reiterate...
Medicines Reports Q4 EPS $0.52 vs $0.24 Est; Revenues $132.2M vs $124.99M Est
Benzinga  Feb 22  Comment 
Medicines (NASDAQ: MDCO) reports fourth-quarter EPS of $0.52 versus the estimated $0.24 per share, beating by +116.7%. Revenues came in at $132.2M versus the estimated $124.99M, beating by +5.8%. (c) 2011 Benzinga.com. All rights reserved. This...
The Medicines Company Reports Full Year and Fourth Quarter 2011 Financial Results
Marketwire  Feb 22  Comment 
PARSIPPANY, NJ -- (Marketwire) -- 02/22/12 -- The Medicines Company (NASDAQ: MDCO) today announced its financial results for the fourth quarter and full year of 2011. Financial highlights for the fourth quarter of 2011: Net revenue increased by 10.5%




RELATED WIKI ARTICLES

Related Articles

more ▼WIKI ANALYSIS
 

Based in Parsippany, NJ, The Medicines Company (MDCO) is engaged in acquiring, developing, and marketing specialty pharmaceutical primarily for cardiovascular indications. Its leading product, Angiomax (bivalirudin), which was acquired from Biogen Idec, Inc. in 1996, is used as an anticoagulant in patients undergoing coronary angioplasty. The company's other late-stage products include Clevidipine and Cangrelor, both acquired from AstraZeneca several years ago. Clevidipine is an intravenous drug (calcium channel blocker) intended for the short-term control of blood pressure in patients undergoing cardiac surgery. Cangrelor is an intravenous anticoagulant, having potential uses in coronary angioplasty and cardiac surgery. The company sells its products through its own sales force and distributors. In 2006, sales of Angiomax helped generate $214.0 million revenue.




References

Retrieved from "http://www.wikinvest.com/stock/Medicines_Company_(MDCO)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki